STABILIZED PROTEIN OR PEPTIDE CONJUGATES

Abstract: A process for extending the half-life in vivo by a biologically active protein or peptide, characterized by covalently coupling said protein or peptide to a polypeptide fragment capable of binding to a serum protein, whereby when administering the resulting protein or peptide congugate its binding to the serum protein results in extended biological activity; the use of the protein or peptide conjugate above for manufacturing a medicament which, when administered to a mammal including man, shows extended half-life in vivo; and a method of therapeutic or prophylactic treatment.

Description: Stabilized protein or peptide conjugates. The present invention relates to the use of biologically ac¬ tive proteins or peptides in the form of products showing improved stability in vivo . i.e. extended half-life, and the invention relates inter alia to the use of recombinant vec¬ tors capable of replication in a host cell to produce such useful products. More specifically, the invention relates to a protein or peptide conjugate capable of selective binding to a host protein or macromolecule , thus stabilizing the bio- logically active protein or peptide m this host. The inven¬ tion also extends to a process for extending the half life in vivo of a biologically active protein or peptide and to the use of a protein or peptide conjugate resulting from such process for the manufacture of a medicament . Although the present invention in the following will be mainly illustrated through protein or peptide conjugates produced by recombinant DNA technology the invention is not limited to such production system but is equally useful when such protein or peptide conjugate is prepared by chemical covalent coupling of its constituents. Gene fusion is a procedure wherein the coding sequence of two or more genes are spliced together to form a combined gene which on expression in a suitable host organism will produce a fusion product wherein the separate proteins or polypeptides coded for by the respective genes are fused together into a single molecule. The rapid depletion of bioactive proteins in vivo is, in some cases, a limiting factor for the efficiency of thera¬ peutic compounds. Examples of products of potential clinical interest with short half-lives in vivo are components such as soluble human CD4, having an interest in the treatment of AIDS, which have a half-life in rabbit of 15 minutes (Watana- be et al., Nature, 337. 1984, 267-270) and human t-PA used m the treatment of blood clots with a halflife of only 2-3 i- nutes in humans (Hollander, Critical Reviews in Biotechn. 6., 1987, 253-271) . Such short half-lives of therapeutically interesting proteins might make it necessary to distribute the compound to the patient either with a high initial dose or with many repeated distributions in order to keep the level of the compound at a clinically relevant level. This reduces the cost e fictiveness of the drug and might cause negative side-effects due to the high doses necessary. To overcome these problems several systems for slow release of drugs have been designed, in which the therapeuti¬ cal is encapsulated by physical means to release the drug in a delayed manner (i.e. entero or depot tablets) or is delive¬ red as a pro drug, inactive until chemically modified within the patient. In this way, * it is in some cases possible to prolong the action of the therapeutical, although the actual in vivo half-life of the compound in circulation has not m- creased. Recently, an alternative strategy has been described using fusions between a recombinant protein and a host prote¬ in such as IgG (Capon et al . , Nature 337. 1989, 525-531) or IgM (Karjalainen et.al. , Nature 339 (1989) 68-70) In this way, the half-life of recombinant soluble CD4 in vivo was shown to be substantially prolonged. However, this strategy of distributing therapeutically interesting compounds have the disadvantage that unwanted immunological reactions are possible and that the half-life of the thus produced recombi- nant fusion protein might not be substantially prolonged. Also for the development of vaccines and other immuno- sti ulatory preparations, a rapid depletion of the antigen from the circulation might decrease the immune response. In order to present the antigen to the immune system in an effi- cient manner different vehicles have been developed, increa¬ sing the immune response. (Allison et al. Journ.of Imm.Me¬ thods, 95 (1986), 157-168). This strategy is often accompanied by simultaneous iniection with weakened or killed pathogens such as in Freund's complete adjuvant (FCA) . However, these formula have the potential risk of being toxic to the receiver and might lead to denaturation of the protein, thus limiting the use of this strategy for the distribution of therapeutical proteins . The present invention provides new improved means to facilitate the stabilization of proteins and polypeptide pro¬ ducts in vivo . According to the present invention this is achieved by coupling, such as by fusion of the desired biolo¬ gically active protein or polypeptide to a binding-protein capable of selective binding to a host protein or macromole- cule thus stabilizing the desired protein in said host. By selective binding to a patient protein with a relatively long half-life, the depletion of the fusion protein is retarded. By the term "patient" used in the present disclosure is in¬ tended a living animal, especially a mammal including man. In accordance with a preferred aspect of the present invention gene fusion is used to combine a first DNA-sequence coding for a bindingprotein with a second DNA-sequence coding for a desired protein or polypeptide into a functional gene capable of expressing the fusion product of said desired bin- ding-protein part. Due to the binding-ability the produced protein or polypeptide is stabilized in vivo in the receptor host. Accordingly, the present invention is based on the surprising finding that the half-life in vivo of a biologi- cally active protein or peptide can be substantially prolong¬ ed by covalently coupling such protein or peptide to a poly¬ peptide fragment capable of binding to a serum protein. This finding was totally unexpected and could not be predicted from available scientific knowledge. Thus, according to one aspect of the invention, there is provided a process for extending the half-life in vivo of a biologically active protein or peptide, such process com¬ prising the steps of covalently coupling the protein or pep¬ tide to a polypeptide- fragment which is capable of binding to a serum protein. When administering the protein or peptide conjugate resulting from such process the bmdning thereof to the serum protein results in substantially extended biologi¬ cal activity due to increased half-life thereof. According to a preferred embodiment of this aspect of the invention said polypeptide fragment is capable of binding to serum albumin, such as a serum albumin of mammal origin, for example human serum albumin. The binding polypeptide fragment of the conjugate pre¬ ferably originates from staphylococcal protein G. Another aspect of the invention s constituted by the use of the protein or peptide conjugate as defined above for the manufacture of a drug or medicament which, when adminis¬ tered to a mammal including man, shows extended halflife in vivo thus prolonging the biological activity of the conjuga¬ te. A preferred aspect of the present invention is thus the provision of a recombinant DNA cloning vehicle or vector comprising a DNA sequence coding for a desired protein or polypeptide operatively linked to a DNA sequence coding for binding mediating part, such that said DNA-sequences together code for a fusion protein of said desired protein or polypep¬ tide, said binding mediating part being capable of selective¬ ly binding to a protein or macromolecule present in the pati¬ ent to be treated.. By transforming a compatible host organism with said vector to permit expression of the above combined DNA sequen¬ ce and culturmg the host organism in a nutrient medium the corresponding binding mediating fusion protein or polypeptide will be produced. Host cells producing functional fusion pro¬ teins should be used, which could be bacterial cells, such as Escherichia or eukaryotic cells, such as fungi, insect cells, plant or mammalian cell cultures. The transformation of the hosts may be effected with well-known methods. Said fusion protein of said desired protein or poly¬ peptide and said binding mediating protein produced by the cultured host organism can be efficiently isolated from the cell culture by means of standard protein purification me- thods such as size exclusion chroma-tography , ion exchange chromatography or affinity purification using a suitable li- gand immobilized to a suitable carrier. If the fusion product is secreted into the surrounding medium the purification may be initiated directly from the medium. If, on the other hand, the fusion product remains within the cells the latter have to be ruptured before such purification can be effected. Rupture of the cell walls may be effected in conventional manner by, e.g., high pressure, ultrasonication, homogenization, shaking with glass-beads etc. In cases where the product is trapped within the peri- plasmic space between two cell membranes, as in gramnegative bacteria, an osmotic shock procedure may be used to release the product into the suspension medium. Any other treatment of the cultured cells or the growth medium prior to the iso¬ lation of the fusion product is, of course, also within the scope of the invention. In conventional manner the said fusion protein in so¬ lution is injected in vivo into the recipient. Due to the part mediating binding to a patient protein or macromolecule the stability of the desired protein or polypeptide is in¬ creased. Alternatively, formation of complexes between said fusion protein and the appropriate patient protein or macro- molecule can be accomplished in vitro . whereafter the said complexes are injected into the recipient. The methods for preparing solution of said fusion pro¬ tein for injection are well-known and need not be described in any detail herein. The conditions suitable for in vitro complex formation should, of course, be chosen with regard to the particular binding mediating protein and desired protein or polypeptide involved. An example of such part mediating specific binding to a patient protein is the albumin binding regions of strepto- coccal protein G. (Nygren et al. , Journ. of Mol.Recogn. 1, (1988), 69-74). Serum albumin with a half-life in humans of 19 days is the most abundant protein in the serum (40g/l) and one of its functions is to bind molecules such as lipids and bilirubin. (T. Peters Jr., Advances in Protein Chemistry, 37 (1985) 161-245). As the albumin-binding regions of streptococcal prote¬ in G, designated A1B1A2B2A3, or parts thereof, have a highly specific binding to serum albumin (Nygren et al . , Journ.of Molec .Recog . 1 (1988) 69-74) it is conceived that this pro- tern could be used to construct recombinant fusion proteins, which bind to serum albumin and are carried around in the patient with a distribution resembling serum albumin. Other examples of parts mediating specific binding to host proteins or macromolecules are receptors, such as the IgG-binding regions of staphylococcal protein A (Uhlen et al., J.Biol.Chem. 259, 1695-1702 (1984)) or streptococcal protein G (Guss et al . EMBO . J . 5, 1567-1575 (1986)) or the staphylococcal fibronectin receptor (Kuusela R. , Nature 276, 718-720 (1978)). One valuable use of such a fusion product is when the protein fused to the part mediating binding to patient prote¬ ins or macromolecules has a therapeutic function. In such cases a prolonged in vivo half-life of the desired protein or polypeptide is essential for its clinical use. Examples of such therapeutic proteins or polypeptides are soluble CD4-re- ceptors for AIDS/HIV-treatment, tissue plasminogen activator (tPA) for dissolving blood clots present in the recipient injected and hormones used for growth stimulation (hGH, IGF- -I, IGF-II, TNF, EGF) or any other clinically relevant func- tion (i.e. insulin, relaxin) . Another valuable use of the invention is for the pro¬ duction of monoclonal and polyclonal antibodies. According to the invention a recombinant protein, to wich one wants to obtain antibodies, is fused to a binding protein to prolong the half-life m circulation n vivo of said recombinant protein. The longer half-life provides a longer exposure to the immune system and thus will give higher titers than conventional methods. Yet another valuable use of the invention is in the production of vaccines. Recombinant proteins used in vaccines can thus be stabilized in vivo , which can make adjuvants su¬ perfluous and m general give higher immunological response. As appears from the above a crucial part of the pre¬ sent invention is the provision of the recombinant DNA struc¬ ture or vector comprising the combined gene coding for the present fusion protein or polypeptide and capable of trans¬ forming a host cell to permit expression thereof and produc¬ tion of the fusion product. The present invention is intended to encompass any such vector irrespective of how it has been obtained using, for example, various restriction enzyme cutting, ligating, transforming and screening techni¬ ques well-known m the art as well as any appropriate vector materials and host-organisms. Thus, the DNA sequence coding for the desired protein or polypeptide may be inserted into a suitable vector and the binding coding DNA sequence inserted subsequently, or vice versa: or the two DNA sequences may be introduced simultaneously into the vector. It is also possib¬ le to insert the respective DNA sequences in parts thereof into the vecto . Further the two DNA sequences may be arran¬ ged with either the binding coding sequence or the sequence coding for the desired protein or polypeptide at the 5 ' -end or start of the combined gene. The special techniques for accomplishing such insertions and combinations with maintai¬ ned correct reading frames, including the provision of suit¬ able restriction sites therefore, are well-known per se in the art. The invention also covers a recombinant DNA molecule comprising the recombinant DNA sequence as described above and fused 3' thereof at DNA level a production gene. By this arrangement such molecule obtains the ability to express a fused protein in a suitable host. Finally, the invention covers a plasmid vector compri- sing the recombinant DNA molecule as described above. The invention also extends to bacterial or eukaryotic cells har¬ bouring the recombinant DNA molecule defined above. The mole¬ cule can be inserted in the chromosome of the cell but may also be contained in a autonomously replicating vector, such as plasmid, phage or virus. The invention will in the following be further illus¬ trated by non-limiting examples with reference to the appen¬ ded drawings wherein: Fig. 1 is a schematic drawing of the streptococcal protein G gene (as described by Olsson et al . in Eur.J. of Biochem. 168, pp 318-324) and the constructs containing frag¬ ments thereof . For comparison is also shown the construct encoding the Z protein. In row A: pEZT; row B: pB2T; row C: the protein G gene and in row D : pBBCD4; Fig. 2 shows the levels of label remaining in the blood circulation during an 18-day period in Maqaque monkeys injected with ^- ^ -I-labelled proteins B2 and Z. Values are relative to levels observed 20 minutes post injection; Fig. 3 shows in lane 1 and 2 an analysis by SDS-PAGE of HSA-affinity purified proteins from the culture medium of E. coli cells harboring pBBCD4 (material in lane 2 is diluted 10 times relative to lane 1.) Lane M: marker proteins with molecular weights as indicated. Fig. 4 is a schematic drawing of the proteins encoded by the different plasmid constructs used in the example: row A: ρBlB2T, row B: pBB-CD4-BB, row C: the complete extracellu¬ lar part of the human CD4 receptor (KabiGen AB, Stockholm, Sweden) ; Fig. 5 shows the result from the modified radioimmuno- assay for the analysis of the biological activity for the BB-CD4-BB fusion protein; and Fig. 6 shows the levels of label remaining in the blood circulation during a 48 hour period in mice injected with ■L25 I-labelled proteins BB, BB-CD4-BB and CD4. Values are relative to levels observed 20 minutes after injection. Starting materials E. coli strain RRIΔM15 (Langley et al . Proc . Nat1.Acad. of Sci. , USA, 72, 1254-1257 (1975)) was used in the examples. The cloning vehicles used were: pEZZT308 (Nygren et al . , J.of Molec . Recogn . 1, 69-74 (1988)) pEG (Eliasson et al . , J.of Biol.Che . 263, 4323-4327 (1988) ) pUC418 (kindly provided by Dan R. Littman at Universi¬ ty of California, San Francisco) . pBlB2 (Nygren et al . , J. of Molec . Recogn . 1, 69-74 (1988) ) . All the strains and vectors are available at the Dept , of Biochemistry, Royal Institute of Technology, Stockholm, Sweden . Plasmid pNP-3 has been deposited on June 14, 1989 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH in Braunschweig, Germany, and given the accession number DSM 5394, in accordance with the Budapest Treaty. Oligonucleotides : NYPE-1 : 5 ' -CGAATTCGCCTAACGGTATGCAGGGAAACAAAGTGGTGCTGGGC-3 ' NYPE-2 : 5 ' -CGGATCCAGGCATCACGATGTCTATTTTGAACTCGAGC-3 ' were custom made by KabiGen AB using solid phase tehnology. PCR reactions were carried out on a Techne programmab¬ le Dri-Block PCH-1. Buffers and Media TSB: Tryptic Soy Broth, made up to one litre and autoclaved. TST: TRIS/HC1 (25mM) pH 7.4, 150 mM NaCl, 0.05% Tween 80. Osmotic Shock solution I: 20% sucrose, 0.3 M TRIS/HC1 pH 8.1, ImM EDTA. Osmotic Shock solution II: 5mM MgCl2 (0°C) . SDS-PAGE loading buffer: 2.5% SDS (sodium dodecyl sulphate), 5% dithiothreitol (DTT) , 1 0 509 0.01% Bromophenol blue. lOx PCR-buffer lOmM TRIS/HC1, pH 8.3, 5mM KC1, 1.5 mM MgCl 2 , 0.01% gelatin PBS: 0.05 M Sodium phosphate pH 7.1, 0.9% NaCl. PCR-amplification An amplification mixture was prepared consisting of the template pUC418 (8 ng/μl), oligonucleotides NYPE-1 and NYPE-2 (each 0.2 μM) , lx PCR-buffer, dNTP' s (each 0.2 M) and 2 units of Taq-polymerase (Stratagene) . The time/temp profile used was 92°C (1 min), 50°C (2 min) and 72°C (1 min) . This cycle was repeated 35 times. Protein labelling After lyophilization proteins were resoluted in dis¬ tilled water to a concentration of 4mg/ml. 100 μg -(25 μl) protein, 50 μl of 0.2 M Na-phosphate buffer (pH7.2), 50 μl Enzymobeads (BioRad Inc.) and 25 μl of 1% (5-glucose was mixed with 1 Ci N 12 ^I (10 μl) and incubated for 20 min. The su¬ pernatant was subsequently loaded on a 5 ml G-25 Superfine Sephadex column (Pharmacia, Sweden) previously equilibrated with PBS (0.1% gelatin) . Elution with the same buffer and collection in small fractions efficiently separated labelled proteins from free Na* 1 * 2* -'!. Affinity purification of proteins Cells harboring the different constructs were grown overnight in Tryptic Soy Broth (TSB) supplemented with Ampi- cillin 70 mg/1. After centrifugation at 5000 g, the periplas- ic content was released using an osmotic shock procedure according to Nossal and Heppel (J. of Biol.Chem. 244, 3049- -3062) involving incubation first with 20% sucrose, 0.3 M TRIS/HC1 pH 8.0, ImM EDTA followed by 0.5 mM MgCl 2 (0°C) . Shock lysates were loaded directly on IgG-Sepharose (Z) or HSA-Sepharose (B2) respectively. After washing with IxTST (25 mM TRIS/HCl pH 7.4, 0.15 M NaCl, 0.05% Tween ® 80) followed by 0.5 mM NH 4 AC , pH 6.G, proteins were eluted with 0.5 M HAc , pH 2.8. The absorbtion at 280 nrn was measured and relevant frac¬ tions were lyophilized. Distribution of proteins m Maqagues Four Maqacues in the range of 6-7 kg were injected with approximately 100 μg of labelled protein using a leg vein. At each sample collection 0.5 ml blood was withdrawn for further analysis. For all samples taken during the 18-day period, the actual measurement of radioactivity was performed on day 18, to eliminate errors due to the half-life of the isotope . Fractionated ammonium sulphate precipitation Precipitation with ammonium sulphate was performed using standard techniques at 40 and 70% of saturation on 150 μl plasma collected 24 hours after injection. Routine Methods Methods used routinely m molecular biology are not described (like the use of commercial restriction enzymes, DNA-ligations , Bal 31 exonuclease, SI nuclease and Klenow polymerase, transformation of E . coli and isolation of plasmid DNA) . In order to analyze protein fractions by SDS-PAGE u- sing the PHAST-system (Pharmacia, Uppsala, Sweden), the samp¬ les were dissolved in loading buffer C2.5% SDS, 5% Dithio- threitol (DTT) and 0.01% Bromphenol blue]. Gradient (8-25% polyacrylamide gels with 5% SDS were run at 10mA for 30 mm and subsequently stained with Coomassie-blue . EXAMPLE 1 Plasmid pEZZT308 (Nygren et al . , Journ.of Mol.Recogn. 1, 69-74 (1988)) , encoding a synthetic divalent IgG-bmding domain, ZZ, preceded by the transcription, translation and secretion signals of staphylococcal protein A (SPA), was di¬ gested with the restriction endonuclease Bgll I , thus relea¬ sing a 174 basepair fragment. After recovery from an agarose gel the vector part was religated to yield pEZT, encoding a single IgG-bmdmg domain Z (Fig. 1) . Eliasson et al. (Journ.of Biol.Che . 263, 4323-4327 (1988)) have described the construction of the plasmid pEG, encoding a protein consisting of the B2 , A3, Cl, Dl and C3- regions of streptococcal protein G, mediating binding to both IgG and HSA. In order to subclone a fragment encoding only a HSA-binding protein, plasmid pEG was digested with restric¬ tion endonucleases Not I and Pst I . releasing a 640 basepair fragment. This was ligated to the purified vector fragment of pEZZT308, previously digested with the same endonucleases. The resulting plasmid pB2T (Fig. 1) encodes a HSA binding protein designated B2 under the same control signals of SPA as above . Over night cultures of E. col cells harboring the plasmid pEZT or pB2T were harvested using an osmotic shock procedure. The lysates were loaded directly on columns of IgG-(Z) or HSA-Sepharose (B2) for affinity chromatography . After lyophilization the purified proteins were resoluted and 12 I-labelled. In total four Maqaque monkeys were intravenously in- jected with labelled proteins. Individuals t. 300 and 233 were given Z-protem and individuals .277 and 278 B-protein. Twen- tyfour hours after injection the distribution of labelled protein within theplasma was analyzed by fractionated ammoni¬ um sulphate precipitation at 40% and 70% of saturation, res- pectively. TABLE 1 Individ- Protein cp . start cpm.pellet cpm.pellet dual ±0% 7_0% 300 Z 14833 11733(79%) 440(3.0%) 233 Z 8615 6069(70%) 426(4.9%) 277 B 17197 260(1.5%) 14273(83%) 278 B 22170 346(1.6%) 18242(82%) As shown in Table 1, in serum originating from apes injected with Z-protein, the majority of label was found in the precipitate at 40% of saturation fraction. This founding was expected as at this level of saturation the precipitate mamly consists of the lmmunoglobulm content of the serum. In contrast, in plasma from monkeys injected with B2- protein, the label was found to be located in the precipitate at 70% of saturation. At this level of saturation the preci¬ pitate mainly consists of serum albumin. These two results indicate that both recombinant proteins behave as expected in vivo as regarded to their respective affinity. Furthermore the clearance of the two proteins in the apes was followed during an 18-day period. Twenty minutes after injection the amount of label present in the blood was determined as a reference value. The levels of label remai¬ ning in the blood during the period was compared to this start value . As can be seen in Fig. 2, the levels of label in both apes injected with Z-protein is rapidly decreasing, approa¬ ching 10% already after 6 days. This effective clearance might in part be explained by immunological responses to com- plexes formed between Z-protein and IgG. Interestingly, in apes injected with B2-protein, the levels of labelled protein present in the blood remains high during the entire 18-days period. After an initial decrease, probably due to a distribution of B2/HSA complexes to the extravascular albumin pool, the levels remaining in both apes resembles the expected decimation as regarded to the turn- over of an average HSA-molecule with a half-life in humans of 19 days. (T. Peters Jr. , Advances in Protein Chemistry, 37, 161-245 (1985)) . EXAMPLE 2 Plasmid pBlB2 was digested with restriction enzymes EcoRI and Sail , treated with lenow polymerase and religated to yield pBlB2 ΔR/S. A synthetic oligonucleotide (5'-TGCAAGATCTTTCAATTTCCCTATCCTCGAGAATTCTAAGCTT-3' and its complementary sequence) was inserted pBlB2 ΔR/S previously cleaved with PstI and Hindi11. giving rise to plasmid pBlB2HIV resistant to Pst I . A multipurpose cloning linker derived from M13mpl8 was cloned between the EcoRI and Hindi 11 restriction sites, resulting m expression of the LacZ' gene positioned immediately downstream. The resulting plasmid was designated pBlB2HIVmpl8. A region encoding am oacidε 1-177 of the mature human CD4 T-cell receptor was in vitro amplified from plasmid pUC418 using the oligonucleotides NYPE-1 and NYPE-2 as pπ- mers for the polymerase chain reaction (PCR) . After digestion with restriction enzymes EcoRI and BamHI the fragment was ligated into the multilinker of pBlB2HIVmpl8 encoding the serum albumin binding domains of streptococcal protein G. The resulting plasmid designated pNP-3 thus encodes a fusion pro- tein consisting of said serum albumin binding region and do¬ mains El and E2 of the human CD4 molecule involved in the binding to glycoprotein gpl20 of HIV-I (Bedinger et al . , Na¬ ture 334 (1988) 162-164). E. coli RR1ΔM15 cells harboring plasmid pNP-3 were cul- tivated at 30°C over night. Analysis on SDS-PAGE on proteins from culture medium affinity purified on HSA-Sepharose shows that the fusion protein is stable the host and has an ap¬ parent molecular weight of 48 kDa (Fig. 3) which is in accor¬ dance with estimations from the deduced ammo acid sequence. EXAMPLE 3 Plasmid pBlB2 was digested with endonucleases EcoRI and Hindi 11 to release a 650 bp fragment encoding the serum albumin binding BB domains of streptococcal protein G. This gene fragment was inserted into plasmid pNP-3 previously di¬ gested with EcoRI and HmdIII. The resulting construction (Fig. i ) designated pEBB-CD4-BB thus encodes a tripartite fusion protein where the CD4 part is flanked by two serum albumin binding regions. E.coli RR1 M15 cells harboring the pEBB-CD4-BB plasmid were grown overnight at 30°C in TSB (Tryptic Soy Broth) containing Ampicill (100 mg/1) . BB- -CD4-BB protein was affinity purified from the culture medium using HSA-Sepharose according to standard procedures. Refe¬ rence CD4 protein containing the complete extracellular regi- on of the human CD4 receptor was obtained from KabiGen (Stockholm, Sweden) . Culture media from an overnight culture of E.coli RR1 M15 cells harboring the plasmid pEBB-CD4-BB was passed through an HSA-Sepharose column. Eluted proteins were analy- zed by SDS-PAGE and a major band was seen, with an apparent Mr of 73.000, as expected from the deduced ammo acid sequen¬ ce . Lyophilized BB-CD4-BB protein was dissolved in PBS- buffer and analyzed for gpl20 binding activity in a modified competitive radio immunoaεsay. Microtiter plates were coated with mouse monoclonal antibodies (F58/H43, P.A. Broliden et al . , 1990, J. of Virology, 5_4, 936-940) for an HIV gpl20 determinant using standard procedures. After washing with PBST-buffer the wells were incubated with gpl20 protein m PBS-buffer (L. Lasky et al. , 1986, Science 233. 209-212) . After rinsing with PBST-buffer, BB-CD4-BB at different concentrations was allow¬ ed to compete with labelled CD4-protem (KabiGen AB, Stockholm, Sweden) in binding to the immobilized gpl20 protein. After washing the cpm in the wells was determined using standard methods. As negative control BB protein was 1o used obtained from cultivation of E.coli cells " harboring plasmid ρBlB2T encoding the BB domain of streptococcal protein G followed by the trpT termination signals (J.Mol .Recognition (1988), 1_ (69-74) . As shown in Fig. 5 the characteristics of the inhibi¬ tion obtained for increasing amounts of BB-CD4-BB is signifi¬ cantly different from the control, indicating a true biologic activity . In order to investigate serum half lifes Balb/C mice were injected using a tail vein with labelled proteins BB, BB-CD4-BB and CD4, respectively. At different time points during a 48 hour period blood samples were taken and the cpm per mg plasma determined. As reference (100%) value, the cpm per mg at 20 mm post injection was used. The results shown m Fig. 6 indicate that the strategy to fuse the CD4 molecule to the serum albumin receptor re¬ sults in an increased serum half-life for this hybrid molecu¬ le (BB-CD4-BB) as compared to the unfused counterpart (CD4) . nternationa Application No: PCT/ SE90 / 00509 MICROORGANISMS Optional Sheet In connection with the microoroanlam referred to on paoβ- -, line. . of the deacription > A. IDENTIFICATION OF DEPOSIT « Further depoalti are identified on an additional aheet Q > Name of depoaitary institution * DSM DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Addrwt of dapoaltary InetrtirtJon (including pottal code and country) * Mascheroder Weg 1 B D-3300 BRAUNSCHWEIG, DE Date of depoaH • Accaaalon Number • 12 June 1989 DSM S 394 S. ADDITIONAL INDICATIONS ' (leave blank if not applicable). This information it continued on a aaparate attached aheet Q C. DESIβNATED STATES FOR WHICH INDICATIONS ARE MADE > (If the Indication! are not for all deaiønated State*) D. SEPARATE FURNISHING OF INDICATIONS • (leave blank If not applicable) The indlcatlont lilted below will be aubrπitted to the International Bureau later • (Specify the general nature ot th* IndlcaUont *.g, " Accetilon Number of Depoilt ") DSM 5394 Thit iheet wat nceived with the International application when filed (to be cheeked by the receiving Office) [~l The dite ot receipt (from th* applicant) by the International Bureau -' (Author lied Officer) Form PCT.RO/134 (Januiry 1981)

Claims: CLAIMS 1. A process for extending the half-life n vivo by a biologically active protein or peptide, characterized by covalently coupling said protein or peptide to a polypeptide fragment capable of binding to a serum protein, whereby when administering the resulting protein or peptide conjugate its binding to the serum protein results in extended biological activity . 2. A process according to claim 1, wherein said covalent coupling is performed by recombinant DNA technology. 3. A process according to claim 1, wherein said covalent coupling is performed chemically. 4. A process according to claim 1, 2 or 3, wherein said polypeptide fragment is capable of binding to serum albumin. 5. A process according to claim 4, wherein said serum albumin is of mammal origin. 6. A process according to any preceding claim, wherein said polypeptide fragment originates from staph lococcal protein A or staphylococcal protein G. 7. The use of the protein or peptide conjugate of any preceding claim for manuf cturing a medicament which, when administered to a mammal including man, shows extended half- life in vivo . 8. The use according to claim 7 , wherein the medicament is an injectable form. 9. The use according to claim 8, wherein the medicament is in the form of an injectable solution or suspension . 10. A method of treating a mammal including man, comprising administering to such mammal a biologically effective amount of a protein or a peptide conjugate as defined herein.

Inventors: NYGREN PER-AAKE, UHLEN MATHIAS, WIGZELL HANS, NYGREN, PER-AAKE, UHLEN, MATHIAS, WIGZELL, HANS
Applicants: CEMU BIOTEKNIK AB
Application year: 1990
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K47, C07K14, C07K19, C12N15, C12P21, C12R1